Null Results in Brief
No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Lara E. Sucheston-Campbell, Rikki Cannioto, Alyssa I. Clay, John Lewis Etter, Kevin H. Eng, Song Liu, Sebastiano Battaglia, Qiang Hu, J. Brian Szender, Albina Minlikeeva, Janine M. Joseph, Paul Mayor, Scott I. Abrams, Brahm H. Segal, Paul K. Wallace, Kah Teong Soh, Emese Zsiros, Hoda Anton-Culver, Elisa V. Bandera, Matthias W. Beckmann, Andrew Berchuck, Line Bjorge, Amanda Bruegl, Ian G. Campbell, Shawn Patrice Campbell, Georgia Chenevix-Trench; on behalf of the Australian Ovarian Cancer Study, Daniel W. Cramer, Agnieszka Dansonka-Mieszkowska, Fanny Dao, Brenda Diergaarde, Thilo Doerk, Jennifer A. Doherty, Andreas du Bois, Diana Eccles, Svend Aage Engelholm, Peter A. Fasching, Simon A. Gayther, Aleksandra Gentry-Maharaj, Rosalind M. Glasspool, Marc T. Goodman, Jacek Gronwald, Philipp Harter, Alexander Hein, Florian Heitz, Peter Hillemmanns, Claus Høgdall, Estrid V.S. Høgdall, Tomasz Huzarski, Allan Jensen, Sharon E. Johnatty, Audrey Jung, Beth Y. Karlan, Reudiger Klapdor, Tomasz Kluz, Bożena Konopka, Susanne Krüger Kjær, Jolanta Kupryjanczyk, Diether Lambrechts, Jenny Lester, Jan Lubiński, Douglas A. Levine, Lene Lundvall, Valerie McGuire, Iain A. McNeish, Usha Menon, Francesmary Modugno, Roberta B. Ness, Sandra Orsulic, James Paul, Celeste Leigh Pearce, Tanja Pejovic, Paul Pharoah, Susan J. Ramus, Joseph Rothstein, Mary Anne Rossing, Matthias Rübner, Joellen M. Schildkraut, Barbara Schmalfeldt, Ira Schwaab, Nadeem Siddiqui, Weiva Sieh, Piotr Sobiczewski, Honglin Song, Kathryn L. Terry, Els Van Nieuwenhuysen, Adriaan Vanderstichele, Ignace Vergote, Christine S. Walsh, Penelope M. Webb, Nicolas Wentzensen, Alice S. Whittemore, Anna H. Wu, Argyrios Ziogas, Kunle Odunsi, Jenny Chang-Claude, Ellen L. Goode and Kirsten B. Moysich
Lara E. Sucheston-Campbell
1College of Pharmacy, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio.
Rikki Cannioto
2Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Alyssa I. Clay
3Cancer Genetic Epidemiology, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota.
John Lewis Etter
2Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Kevin H. Eng
4Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
Song Liu
4Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
Sebastiano Battaglia
5Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York.
Qiang Hu
4Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
J. Brian Szender
6Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Albina Minlikeeva
2Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Janine M. Joseph
2Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Paul Mayor
6Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Scott I. Abrams
7Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York.
Brahm H. Segal
7Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York.
8Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
Paul K. Wallace
9Department of Flow & Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York.
Kah Teong Soh
9Department of Flow & Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York.
Emese Zsiros
6Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Hoda Anton-Culver
10Genetic Epidemiology Research Institute, School of Medicine, University of California Irvine, Irvine, California.
Elisa V. Bandera
11Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Matthias W. Beckmann
12Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Andrew Berchuck
13Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Line Bjorge
14Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway.
15Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
Amanda Bruegl
16Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon.
Ian G. Campbell
17Cancer Genetics Laboratory, East Melbourne, Australia.
18Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.
Shawn Patrice Campbell
16Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon.
Georgia Chenevix-Trench
19Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, Australia.
Daniel W. Cramer
20Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.
21Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Agnieszka Dansonka-Mieszkowska
22Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Fanny Dao
23Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Brenda Diergaarde
24Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Thilo Doerk
25Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany.
Jennifer A. Doherty
26Department of Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Andreas du Bois
27Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
28Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.
Diana Eccles
29Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
30Wessex Clinical Genetics Service, Southampton University Hospitals Trust, Southampton, United Kingdom.
Svend Aage Engelholm
31Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Peter A. Fasching
12Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Simon A. Gayther
32Center for Cancer Prevention and Translational Genomics, Cedars-Sinai Medical Center, Los Angeles, California.
33Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Aleksandra Gentry-Maharaj
34Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
Rosalind M. Glasspool
35The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Marc T. Goodman
36Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
37Department of Biomedical Sciences, Community and Population Health Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Jacek Gronwald
38Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Philipp Harter
27Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
Alexander Hein
12Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Florian Heitz
27Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
28Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.
Peter Hillemmanns
25Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany.
Claus Høgdall
39Department of Gynaecology, Rigshospitalet, University of Copenhagen, Herlev, Denmark.
Estrid V.S. Høgdall
40Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
41Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Tomasz Huzarski
38Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Allan Jensen
40Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Sharon E. Johnatty
19Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, Australia.
Audrey Jung
42Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
43University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Heidelberg, Germany.
Beth Y. Karlan
44Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Reudiger Klapdor
25Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany.
Tomasz Kluz
45Clinic of Obstetrics and Gynecology, Institute of Midwifery and Emergency Medicine, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland.
Bożena Konopka
22Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Susanne Krüger Kjær
39Department of Gynaecology, Rigshospitalet, University of Copenhagen, Herlev, Denmark.
40Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Jolanta Kupryjanczyk
22Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Diether Lambrechts
46Department of Oncology, Laboratory for Translational Genetics, Vesalius Research Center, University of Leuven, Leuven, Belgium.
Jenny Lester
44Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Jan Lubiński
38Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Douglas A. Levine
23Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Lene Lundvall
47Department of Gynecology, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Valerie McGuire
48Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Iain A. McNeish
49Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, United Kingdom.
Usha Menon
34Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
Francesmary Modugno
24Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
50Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
51Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Roberta B. Ness
52The University of Texas School of Public Health, Houston, Texas.
Sandra Orsulic
44Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
James Paul
35The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Celeste Leigh Pearce
53Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
54Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Tanja Pejovic
16Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon.
55Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Paul Pharoah
56Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
57Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Susan J. Ramus
58School of Women's and Children's Health, University of New South Wales, New South Wales, Australia.
59The Kinghorn Cancer Centre, Garvan Institute of Medical Research, New South Wales, New South Wales, Australia.
Joseph Rothstein
48Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Mary Anne Rossing
60Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
61Department of Epidemiology, University of Washington, Seattle, Washington.
Matthias Rübner
12Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Joellen M. Schildkraut
62Department of Public Health Sciences, The University of Virginia, Charlottesville, Virginia.
Barbara Schmalfeldt
63Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ira Schwaab
64Praxis für Humangenetik, Wiesbaden, Germany.
Nadeem Siddiqui
65Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Weiva Sieh
66Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.
67Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Piotr Sobiczewski
68Department of Gynecologic Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Honglin Song
56Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Kathryn L. Terry
20Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.
21Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Els Van Nieuwenhuysen
69Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Adriaan Vanderstichele
69Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Ignace Vergote
69Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Christine S. Walsh
44Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Penelope M. Webb
70Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Australia.
Nicolas Wentzensen
71Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Alice S. Whittemore
48Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Anna H. Wu
54Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Argyrios Ziogas
72Department of Epidemiology, University of California Irvine, Irvine, California.
Kunle Odunsi
6Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Jenny Chang-Claude
42Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
43University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Heidelberg, Germany.
Ellen L. Goode
73Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.
Kirsten B. Moysich
2Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
DOI: 10.1158/1055-9965.EPI-16-0631 Published March 2017
Article Figures & Data
Figures
- Figure 1.
These five concentric circles are circular standard Manhattan plots. The chromosome is on the outer circle, −log10 P values are on the y-axis (vertical), with each circle representing the P value from single SNP tests of association with overall survival adjusted for age, stage, and grade. A–E, The Manhattan plots are as follows: all ovarian cancer cases (A); high-grade serous (B); mucinous cell (C); endometrioid (D); and clear cell (E). The red dashed line designates P = 0.01, −log10(P value) = 2, with all red-colored SNPs above that line reflecting SNPs P < 0.01.
Tables
- Table 1.
Clinical characteristics of invasive EOC cases from the Ovarian Cancer Association Consortium analyzed for association with MSDC genetic variation
Vital status at last follow-up Patient characteristics Alive Deceased Total invasive EOC cases n = 5,243 (48.8%) n = 5,508 (51.2%) N = 10,751 Age at diagnosis <50 years 1,627 (59.1%) 1,125 (40.9%) 2,752 50–69 years 3,100 (47.4%) 3,445 (52.6%) 6,545 70+ years 516 (35.5%) 938 (64.5%) 1,454 Histology Serous 2,765 (39.7%) 4,207 (60.3%) 6,972 High-grade serous 2,210 (38.2%) 3,568 (61.8%) 5,578 Mucinous 504 (72.1%) 197 (27.9%) 701 Endometrioid 1,058 (68.7%) 485 (31.3%) 1,543 Clear cell 529 (67.1%) 260 (32.9%) 789 Mixed cell 215 (56.7%) 166 (43.3%) 381 Undifferentiated/poorly differentiated 92 (42.6%) 124 (57.4%) 216 Unknown epithelial 70 (49.6%) 69 (50.3%) 139 Grade Well differentiated 757 (70.5%) 316 (29.3%) 1,073 Moderately differentiated 1,107 (50.6%) 1,079 (49.4%) 2,186 Poorly differentiated 2,185 (42.4%) 2,969 (57.6%) 5,154 Undifferentiated 284 (46.8%) 323 (53.2%) 607 Unknown 583 (58.1%) 419 (41.9%) 1,002 Stage Localized 1,393 (81.3%) 320 (18.7%) 1,713 Regional 1,314 (66.4%) 665 (33.6%) 1,979 Distant 2,109 (34.3%) 4,034 (65.7%) 6,134 Unknown 178 (55.5%) 143 (44.5%) 321
March 2017
Volume 26, Issue 3
Volume 26, Issue 3
No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Lara E. Sucheston-Campbell, Rikki Cannioto, Alyssa I. Clay, John Lewis Etter, Kevin H. Eng, Song Liu, Sebastiano Battaglia, Qiang Hu, J. Brian Szender, Albina Minlikeeva, Janine M. Joseph, Paul Mayor, Scott I. Abrams, Brahm H. Segal, Paul K. Wallace, Kah Teong Soh, Emese Zsiros, Hoda Anton-Culver, Elisa V. Bandera, Matthias W. Beckmann, Andrew Berchuck, Line Bjorge, Amanda Bruegl, Ian G. Campbell, Shawn Patrice Campbell, Georgia Chenevix-Trench, Daniel W. Cramer, Agnieszka Dansonka-Mieszkowska, Fanny Dao, Brenda Diergaarde, Thilo Doerk, Jennifer A. Doherty, Andreas du Bois, Diana Eccles, Svend Aage Engelholm, Peter A. Fasching, Simon A. Gayther, Aleksandra Gentry-Maharaj, Rosalind M. Glasspool, Marc T. Goodman, Jacek Gronwald, Philipp Harter, Alexander Hein, Florian Heitz, Peter Hillemmanns, Claus Høgdall, Estrid V.S. Høgdall, Tomasz Huzarski, Allan Jensen, Sharon E. Johnatty, Audrey Jung, Beth Y. Karlan, Reudiger Klapdor, Tomasz Kluz, Bożena Konopka, Susanne Krüger Kjær, Jolanta Kupryjanczyk, Diether Lambrechts, Jenny Lester, Jan Lubiński, Douglas A. Levine, Lene Lundvall, Valerie McGuire, Iain A. McNeish, Usha Menon, Francesmary Modugno, Roberta B. Ness, Sandra Orsulic, James Paul, Celeste Leigh Pearce, Tanja Pejovic, Paul Pharoah, Susan J. Ramus, Joseph Rothstein, Mary Anne Rossing, Matthias Rübner, Joellen M. Schildkraut, Barbara Schmalfeldt, Ira Schwaab, Nadeem Siddiqui, Weiva Sieh, Piotr Sobiczewski, Honglin Song, Kathryn L. Terry, Els Van Nieuwenhuysen, Adriaan Vanderstichele, Ignace Vergote, Christine S. Walsh, Penelope M. Webb, Nicolas Wentzensen, Alice S. Whittemore, Anna H. Wu, Argyrios Ziogas, Kunle Odunsi, Jenny Chang-Claude, Ellen L. Goode and Kirsten B. Moysich on behalf of the Australian Ovarian Cancer Study
Cancer Epidemiol Biomarkers Prev March 1 2017 (26) (3) 420-424; DOI: 10.1158/1055-9965.EPI-16-0631
No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Lara E. Sucheston-Campbell, Rikki Cannioto, Alyssa I. Clay, John Lewis Etter, Kevin H. Eng, Song Liu, Sebastiano Battaglia, Qiang Hu, J. Brian Szender, Albina Minlikeeva, Janine M. Joseph, Paul Mayor, Scott I. Abrams, Brahm H. Segal, Paul K. Wallace, Kah Teong Soh, Emese Zsiros, Hoda Anton-Culver, Elisa V. Bandera, Matthias W. Beckmann, Andrew Berchuck, Line Bjorge, Amanda Bruegl, Ian G. Campbell, Shawn Patrice Campbell, Georgia Chenevix-Trench, Daniel W. Cramer, Agnieszka Dansonka-Mieszkowska, Fanny Dao, Brenda Diergaarde, Thilo Doerk, Jennifer A. Doherty, Andreas du Bois, Diana Eccles, Svend Aage Engelholm, Peter A. Fasching, Simon A. Gayther, Aleksandra Gentry-Maharaj, Rosalind M. Glasspool, Marc T. Goodman, Jacek Gronwald, Philipp Harter, Alexander Hein, Florian Heitz, Peter Hillemmanns, Claus Høgdall, Estrid V.S. Høgdall, Tomasz Huzarski, Allan Jensen, Sharon E. Johnatty, Audrey Jung, Beth Y. Karlan, Reudiger Klapdor, Tomasz Kluz, Bożena Konopka, Susanne Krüger Kjær, Jolanta Kupryjanczyk, Diether Lambrechts, Jenny Lester, Jan Lubiński, Douglas A. Levine, Lene Lundvall, Valerie McGuire, Iain A. McNeish, Usha Menon, Francesmary Modugno, Roberta B. Ness, Sandra Orsulic, James Paul, Celeste Leigh Pearce, Tanja Pejovic, Paul Pharoah, Susan J. Ramus, Joseph Rothstein, Mary Anne Rossing, Matthias Rübner, Joellen M. Schildkraut, Barbara Schmalfeldt, Ira Schwaab, Nadeem Siddiqui, Weiva Sieh, Piotr Sobiczewski, Honglin Song, Kathryn L. Terry, Els Van Nieuwenhuysen, Adriaan Vanderstichele, Ignace Vergote, Christine S. Walsh, Penelope M. Webb, Nicolas Wentzensen, Alice S. Whittemore, Anna H. Wu, Argyrios Ziogas, Kunle Odunsi, Jenny Chang-Claude, Ellen L. Goode and Kirsten B. Moysich on behalf of the Australian Ovarian Cancer Study
Cancer Epidemiol Biomarkers Prev March 1 2017 (26) (3) 420-424; DOI: 10.1158/1055-9965.EPI-16-0631
Jump to section
Advertisement